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Recently in Cell Reports, Goel et al. (2014) identified mechanisms underlying cellular heterogeneity in triple
negative breast cancer. They find that expression of a6 integrin and its splice variants differs between epithe-
lial and mesenchymal tumor cell subpopulations, the latter of which relies on VEGF signaling to promote
cancer stem cell function.A small number of tumor initiating cells
(TICs) within a given tumor are thought
to represent the subpopulation capable
of self-renewal and tumor initiation and
to likely give rise to the heterogeneous
tumor cell populations observed in many
cancer types. These TICs, also known
as cancer stem cells (CSCs), have been
established as drivers of tumor progres-
sion, drug resistance, and disease relapse
(Visvader and Lindeman, 2012). In
contrast, cancers may not strictly
conform to this hierarchical organization,
but instead present a phenotypic plas-
ticity where non-TICs can dedifferentiate
or reprogram and acquire TIC-like proper-
ties in response to changes in the micro-
environment (Gupta et al., 2009). Because
of its presence in many stem cell niches
and its ability to support cell adhesion
and signaling by binding to integrins, the
basement membrane has the capacity to
regulate stem cell behavior (Desgrosellier
and Cheresh, 2010). Laminin-binding
integrins containing the a6 subunit
(CD49f) mediate signals from the base-
ment membrane and have been used as
a marker for enrichment of adult stem
cells, progenitor cells, and TICs (Stingl
et al., 2006; Yoshioka et al., 2013). How-
ever, there is some controversy as to
whether a6 is associated with tumor
stemness and whether this marker can
drive the process of tumor initiation (Vis-
vader and Lindeman, 2012).
In a recent study in Cell Reports, Goel
and colleagues report that the TIC-
enriched CD44high/CD24low population
in triple negative breast cancer, while
thought to represent the stem-like popu-
lation, is composed of distinct epithelial
and mesenchymal subpopulations that
can be identified by their overall level ofa6 expression, in particular the preva-
lence of the a6A as compared to the
a6B cytoplasmic domain splice variant,
respectively (Figure 1). Compared to the
epithelial morphology of the a6 high
population, the a6 low population had a
distinct mesenchymal morphology and
expressed higher levels of EMT markers,
HIF-1a, and VEGF. The epithelial sub-
population expressed higher levels of
the b4 integrin subunit to favor a6b4 inte-
grin heterodimer pairs, whereas a6
tended to form heterodimers with the b1
subunit in the mesenchymal subpopula-
tion. Expression of these distinct integrin
signaling units likely drives unique down-
stream signaling events, which in turn
may differentially impact the biological
behavior of these cells. Using tran-
scription activator-like effector nuclease
(TALEN) technology to specifically knock
down the expression of the a6B variant,
Goel et al. concluded that this variant is
critically required to drive mammosphere
formation and anchorage-independent
growth. In addition, the authors revealed
that the a6B variant regulates the ex-
pression of the a6A variant, suggesting
that integrin a6B drives a mesenchymal
phenotype.
Accordingly, Goel et al. highlight a
potential opportunity to target the a6B
splice variant as a means to impair the
mesenchymal TIC component of triple
negative breast cancer. To realize this
potential, it is necessary to understand
how the expression of a6B is regulated.
By comparing the epithelial and mesen-
chymal populations for their expression
of a number of specific splicing factors
that have previously been implicated in
epithelial differentiation, EMT, and cancer
stem cells, the authors found that theCell Stem Cemesenchymal population expressed
lower levels of ESRP1. This pattern was
confirmed in clinical samples of triple
negative breast cancers, which showed
preferential expression of the a6B variant
and an inverse correlation between
expression of a6B and the epithelial
splicing factor ESRP1. Mechanistically,
Goel and colleagues established that
the high levels of VEGF present in triple
negative breast cancers induce high
levels of GLI1 and BMI1 to suppress the
expression of ESRP1, thus favoring pro-
duction of the integrin a6B splice variant.
This finding is consistent with a recent
study reporting development of a potent
BMI1 inhibitor that abolished tumor initia-
tion and self-renewal capacities for colo-
rectal cancers (Kreso et al., 2014). In this
light, BMI1 might represent a druggable
target to disrupt the mesenchymal
component of triple negative breast
cancers. This study mirrors a recent
Cell Stem Cell publication by Todaro and
colleagues (Todaro et al., 2014) who
report that under certain conditions, colo-
rectal cancer cells express a CD44v6
variant that identifies and drives a highly
tumorigenic TIC population with meta-
static potential. While these two reports
suggest that some TIC markers are func-
tional contributors to cancer progression,
they demonstrate that only particular iso-
forms of well-established markers may
truly be relevant for the TIC phenotype.
Although in this study, Goel and
colleagues revealed the importance of
the alternative splicing variant in the func-
tion of integrin a6, additional questions
remain to be answered. Understanding
why a6B, and not a6A, can drive TIC
behavior may lead to specific approaches
to target this pathway. It will be importantll 14, May 1, 2014 ª2014 Elsevier Inc. 557
?Figure 1. Integrin Splice Variant a6B Contributes to Cancer
Stemness
High levels of VEGF favor integrin a6B expression by inhibiting the alternative
splicing factor ESRP1 that promotes expression of the a6A variant. When
expressed on triple negative breast cancer cells, integrin a6B promotes
self-renewal and tumor initiation and upregulates EMT markers by an unde-
fined signaling network that warrants further investigation. The question
mark highlights another question: is a6B binding to laminin or another soluble
matrix protein necessary to drive this pathway, or might the integrin function
independent of adhesion?
Cell Stem Cell
Previewsto discernwhetherdifferences
in b1 subunit composition
result in different affinities for
laminin in the epithelial versus
mesenchymal populations. It
is also possible that the a6B
variant promotes anchorage-
independent growth, a hall-
mark of cancer progression
that can involve integrin
signaling in the absence of an
integrin ligand (Desgrosellier
et al., 2009). This possibility is
particularly relevant since
the authors find that a6B
expression drives a switch
from expressing a6Ab4 to
a6Bb1 integrin, which pro-
motes cell survival under
anchorage-independent con-
ditions. Accordingly, resolving
the different partners and
signaling pathways that drive
TIC properties specifically
downstream of a6Bb1 will be
critical for developing specific
targeting approaches.
Recently, Malanchi et al.
proposed that the TIC pheno-
type can change and evolve
based on physical interac-
tions with the local microenvi-ronment (Malanchi et al., 2012). Such
plasticity is also a hallmark of EMT, a
process capable of triggering the emer-
gence of TICs. Tumor microenvironments
possess numerous factors capable of
inducing EMT gene programs which
could, in turn, impose TIC-like states.
Numerous cellular mechanisms are com-
promised under the hypoxic conditions
that arise during tumor progression, and
in the setting of cancer therapy, they
trigger pathways that allow cancer cells
to adapt to this hostile environment.
Among these, hypoxia-inducible factors558 Cell Stem Cell 14, May 1, 2014 ª2014 El(HIFs) are strong inducers of VEGF
expression, which not only promotes
angiogenesis but also directly influences
the behavior of tumor cells. The study
by Goel et al. highlights a role for VEGF
in the regulation of a6 integrin splicing
to drive expression of the a6B variant
that serves as a functional driver of both
the TIC and EMT phenotypes. In fact,
this pathway may link changes in the
tumor microenvironment to behavior
that is often associated with TIC acti-
vity. Although further studies will be
necessary to fully understand how andsevier Inc.why a6Bb1 drives TIC proper-
ties, Goel and colleagues
have discovered an important
new distinction that defines
the aggressive mesenchymal
component of triple nega-
tive breast cancer, and
they have identified several
critical nodes by which this
pathway could be targeted
therapeutically.
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